Abstracts tagged "osteoporosis"

Abstract Number: 1138 • ACR Convergence 2021
Assessing Trends in Dual Energy X-Ray Absorptiometry (DXA) Utilization Among Medical Providers in the United States
Timothy Edgil¹, Kenneth Saag², Jeffrey Curtis³ and Maria I. Danila², ¹Division of General Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The twenty first century has seen falling reimbursement rates for dual energy X-ray absorptiometry (DXA) testing coupled with a rising elderly population in the…
Abstract Number: 1139 • ACR Convergence 2021
Fracture Liaison Service Outcomes at a Southern California County Hospital Highlights Need for Health System Improvements
Muntarin Karim¹, lorien ahn², Jordan Thompson¹, Christina Downey³, Lorena Salto⁴ and Karina Torralba⁵, ¹Loma Linda University, Redlands, CA, ²loma linda university medical center, Loma Linda, CA, ³Loma Linda University Medical Center, Redlands, CA, ⁴Loma Linda University Health, Loma Linda, CA, ⁵Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA
Background/Purpose: Osteoporosis causes significant morbidity and mortality in the elderly. Despite the benefits of treatment, < 25% of elderly patients who fracture receive treatment. A…
Abstract Number: 1140 • ACR Convergence 2021
Fracture Risk in DXA-Appropriate Patients on Glucocorticoids: Is Everyone Tested According to Screening Guidelines?
Alexandra Chop¹, Rajesh Kupuraju¹, Ruchi Patel¹, Kristen Salava¹, Madhuri Duggirala¹, Aparna Baburaj¹, Andrea Berger², Jason Brown¹ and David Bulbin³, ¹Geisinger Medical Center, Danville, PA, ²Department of Population Health Sciences, Geisinger Medical Center, Danville, PA, ³Geisinger Health System, Danville, PA
Background/Purpose: Glucocorticoids are commonly prescribed for a multitude of indications, yet have many side effects, one of which is glucocorticoid induced osteoporosis (GIOP). The 2017…
Abstract Number: 1141 • ACR Convergence 2021
Factors Associated with Fragility Fracture in Patients with Systemic Mastocytosis: Data from an Inception Cohort in a Single Centre
Karen Carpio Astudillo¹, Filip Skrabski², ISABEL CASTREJON³, Jose Maria Alvaro-Gracia², Alicia Garcia Prieto² and Teresa González⁴, ¹Hospital General Universitario Gregorio Maraon, Madrid, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Pfizer Spain, Chicago, ⁴H Gregorio Maraon, Madrid, Spain
Background/Purpose: Systemic Mastocytosis (SM) is a very rare disease (0,5 -1 per 10000 in adults). Most common manifestations are skin related or anaphylaxis, however almost…
Abstract Number: 1143 • ACR Convergence 2021
Predictors of Engagement in Bone Health Care Among Rural Veterans at Risk for Osteoporosis
Karla Miller¹, Kimberly McCoy², Christopher Richards², Aaron Seaman³ and Samantha Solimeo⁴, ¹Department of Internal Medicine, Rheumatology Section, Veterans Affairs Salt Lake City Health Care System; Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT, ²VA Office of Rural Health, Veterans Rural Health Resource Center-Iowa City; Comprehensive Access & Delivery Research and Evaluation, Department of Veterans Affairs, CADRE, Iowa City VA HCS, Iowa City, IA, ³VA Office of Rural Health, Veterans Rural Health Resource Center-Iowa City (VRHRC-IC); Division of Genera l Internal Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, ⁴VA Office of Rural Health, Veterans Rural Health Resource Center-Iowa City; Comprehensive Access & Delivery Research and Evaluation; and Primary Care Analytics Team Iowa City (PCAT-IC), Department of Veterans Affairs, CADRE, Iowa City VA HCS Division of General Internal Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: A virtual bone health team (BHT) model was implemented to identify, screen, and treat rural Veterans at risk for osteoporosis. This study was conducted…
Abstract Number: 1145 • ACR Convergence 2021
Prevalence of and Risk Factors for Vertebral Fractures and Low Bone Mass Density Among Women Aging with HIV in Peru
Diego Cabrera¹, Mijahil P. Cornejo², Rebecca Slotkin³, Yvett Pinedo⁴, Wei Yu⁵, Wenmin Guan⁵, Patricia J. Garcia⁶ and Evelyn Hsieh⁷, ¹Yale School of Medicine, Lima, Peru, ²Grunenthal peruana, Lima, Peru, ³Yale New Haven Hospital, New Haven, CT, ⁴Hospital Nacional Arzobispo Loayza, Lima, Peru, ⁵Department of Radiology, Chinese Academy of Medicine Sciences and Peking Union Medical College Hospital, Beijing, China (People's Republic), ⁶Universidad Peruana Cayetano Heredia, Lima, Peru, ⁷Yale School of Medicine, New Haven, CT
Background/Purpose: Few studies in Latin America and the Caribbean have evaluated osteoporosis and fracture epidemiology among populations at increased risk for secondary osteoporosis, such as…
Abstract Number: 1146 • ACR Convergence 2021
Study of Vertebral and Femur Fracture Prevalence and Scanographic Bone Attenuation Coefficient of the First Lumbar Vertebra in an Academic Hospital Setting
Zareen Vaghaiwalla¹, Paul Wasserman¹ and Gurjit Kaeley², ¹University of Florida College of Medicine Jacksonville, Jacksonville, FL, ²University of Florida, Jacksonville, FL
Background/Purpose: Patients with osteoporosis are prone to suffer fragility fractures leading to an increased risk of future fractures. Detection of osteoporosis has been led by…
Abstract Number: 1148 • ACR Convergence 2021
Prevalence and Risk Factors of Insufficiency Fractures of the Foot and Ankle Joint in Rheumatic and Musculoskeletal Diseases
Bjoern Buehring¹, Nadine Al-Azem¹, Ioana Andreica¹, David Kiefer², Uta Kiltz¹, Styliani Tsiami¹, Xenofon Baraliakos¹ and Juergen Braun¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Essen, Germany
Background/Purpose: Unlike fragility fractures, high-trauma and insufficiency fractures (IF) are not classically considered osteoporotic fractures. Patients with rheumatic and musculoskeletal diseases (RMD), especially those with…
Abstract Number: 1325 • ACR Convergence 2021
Osteoporosis in Psoriatic Arthritis
Sara M. Rojas Herrera¹, Ignacio Braña Abascal¹, Maria Priego Fernanddez-Martos¹, Delia Fernandez Lozano¹, Lara M. Chaves Chaparro¹, Raul Veroz Gonzalez¹, Juan J. Aznar Sanchez² and Eugenio Chamizo Carmona¹, ¹Hospital de Mérida, Mérida, Spain, ²Hospital de Mérida, Merida, Spain
Background/Purpose: Osteoporosis (OP) is a frequently underestimated comorbidity in immune-mediated inflammatory diseases (IMIDs). Its association with IMIDs is worse characterized in Psoriatic Arthritis (PsA) than…
Abstract Number: 0445 • ACR Convergence 2021
Safety and Efficacy of Denosumab vs Risedronate in Patients with Glucocorticoid-Induced Osteoporosis and Rheumatoid Arthritis
Jonathan Adachi¹, Arkadi Chines², Shuang Huang², Kenneth Saag³, Willem Lems⁴ and Piet Geusens⁵, ¹McMaster University/St. Joseph's Healthcare, Hamilton, ON, Canada, ²Amgen Inc., Thousand Oaks, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴VUmc, Amsterdam, Netherlands, ⁵Maastricht University, Genk, Belgium
Background/Purpose: Denosumab (DMAb) is approved for the treatment of glucocorticoid (GC)–induced osteoporosis (GiOP). In a phase 3, international, active-controlled, double-blind, double-dummy study, treatment with DMAb…
Abstract Number: 0446 • ACR Convergence 2021
Clinical Characteristics, Including History of Myocardial Infarction and Stroke, Among US PMO Women Initiating Treatment with Romosozumab and Other Anti-osteoporosis Therapies
Jay Lin¹, Carrie Nielson¹, Mary Oates¹, Cynthia Deignan² and Zhigang Yu¹, ¹Amgen Inc., Thousand Oaks, CA, ²Amgen, Inc., Agoura Hills, CA
Background/Purpose: This study is an ongoing USFDA post-marketing requirement (2020-2024) to assess the impact of boxed warning on romosozumab (romo) treatment and the feasibility of…
Abstract Number: 0447 • ACR Convergence 2021
Bone Anabolic Effects of a Novel Orally-Available Small Molecule SIK2/SIK3 Inhibitor
Cheng-Chia Tang¹, Shiv Verma¹, Steve De Vos², David Amantini³, Philippe Clement-Lacroix³, Nicolas Desroy³, Antonio Speziale⁴, Daniel Brooks⁵, Mary Bouxsein⁵, Janaina da Silva Martins¹, Yingshe Zhao⁶, Henry Kronenberg¹ and Marc Wein¹, ¹MGH Endocrine Unit, Boston, MA, ²Galapagos NV, Mechelen, Belgium, ³Galapagos SASU, Romainville, France, ⁴Galapagos GmbH, Basel, Switzerland, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶MGH Endocrine Unnit, Boston, MA
Background/Purpose: Orally-available bone anabolic agents represent a major unmet medical need for patients with osteoporosis. Widespread use of parathyroid hormone (PTH)-based osteo-anabolic therapies is limited…
Abstract Number: 0448 • ACR Convergence 2021
Bone Microarchitecture Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as Predictor of Incident Fracture in Rheumatic Disease Patients on Long-term Glucocorticoid- a Five-year Longitudinal Study
ho SO¹, Xerox Lau¹, Vivian Hung¹, Steve Pang², Shirley Ying³, Kitty Kwok⁴, Ka Lai Lee⁵, Jolly Lee⁶, Jack Lee¹, James Griffith¹, Ling Qin¹ and Lai-Shan Tam⁷, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Kwong Wah Hospital, Hong Kong, Hong Kong, ³Prince Margaret Hospital, Hong Kong, Hong Kong, ⁴Queen Elizabeth Hospital, Hong Kong, Hong Kong, ⁵Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong, ⁶Tai Po Hospital, Hong Kong, Hong Kong, ⁷Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic)
Background/Purpose: Impaired bone quality and strength estimated by high resolution peripheral quantitative computer tomography (HR-pQCT) in patients with rheumatic diseases on long-term glucocorticoid (LTGC) therapy…
Abstract Number: 0653 • ACR Convergence 2021
Adherence to the 2015 ACR Guidelines for the Management of Polymyalgia Rheumatica and Screening for Osteoporosis at a Tertiary Care Medical Center
Padmini Parameswaran¹ and Michael Lucke², ¹Allegheny Health Network Medical Education Consortium, Pittsburgh, PA, ²Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Since the first description of polymyalgia rheumatica (PMR) in the early 1950s, the ideal dose and duration of glucocorticoid therapy has varied. In 2015,…
Abstract Number: 0107 • ACR Convergence 2020
Effects of Abaloparatide on Modeling and Remodeling Based Bone Formation
David W Dempster¹, Hua Zhou¹, Sudhaker D Rao², Chris Recknor³, Paul D Miller⁴, Benjamin Z Leder⁵, Miriam Annett⁶, Michael S Ominsky⁶ and Bruce H Mitlak⁶, ¹Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, West Haverstraw, NY, ²Bone & Mineral Research Laboratory, Henry Ford Health System, Detroit, MI, Detroit, MI, ³United Osteoporosis Centers, Gainesville, GA, Gainesville, GA, ⁴Colorado Center for Bone Research, Lakewood, CO, Lakewood, CO, ⁵Mass General Hospital, Harvard Medical School, Boston, MA, Boston, MA, ⁶Radius Health, Inc., Waltham, MA, Waltham, MA
Background/Purpose: To evaluate abaloparatide-induced changes in the bone formation indices of mineralizing surface (MS), bone formation rate (BFR) and mineral apposition rate (MAR); and to…

« Previous Page
1
…
8
9
10
11
12
…
20
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].